To investigate a clinical implication of DICAM in MS, we analyzed a possible association between sDICAM in CSF of 43 untreated patients with RRMS and the biomarker of neuroaxonal damage neurofilament light chain (NfL) (17) and the astrocyte activity biomarker glial fibrillary acidic protein (GFAP) (18). Here, NEFL is linked to myeloid sarcoma.